Literature DB >> 2877832

N-(4-hydroxyphenyl)-all-trans-retinamide pharmacokinetics in female rats and mice.

T A Hultin, C M May, R C Moon.   

Abstract

The distribution of N-(4-hydroxyphenyl)-all-trans-retinamide (4-HPR) and its metabolites was investigated in the liver, serum, mammary gland, and urinary bladder of female rats and mice. Following an iv dose of 5 mg/kg to rats, 4-HPR distributed to all tissues examined with the highest levels reached in the liver. The distribution period was completed in about 4 hr and was followed by first order elimination kinetics. The t1/2 for 4-HPR elimination from the liver was 9.4 hr, from the serum was 12.0 hr (not significantly different from liver), from the mammary gland was 43.6 hr, and from the urinary bladder was 9.3 hr. A 5-day ip dosing study (5 mg/kg/day of 4-HPR) in both rats and mice revealed that 4-HPR distributed to all tissues examined with the highest levels reached in the urinary bladder. 4-HPR and four metabolites were detected in the tissues. One coeluted with a cis isomer of 4-HPR (M2), another with N-(4-methoxyphenyl)-all-trans-retinamide (4-MPR) (M3), a third appeared to be a 4-HPR-ester (M4), and the fourth remains unidentified (M1). However, the amount of each metabolite varied between tissues and between species. The concentration of 4-HPR was significantly 2-4 times lower and the percentage of M3 (4-MPR) was 3 times higher in the mouse tissues than in the corresponding tissues of the rat. M2 (cis-4-HPR) and M4 (4-HPR-ester) were present in rat liver but not in mouse liver.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2877832

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  6 in total

1.  Development of PLGA-based injectable delivery systems for hydrophobic fenretinide.

Authors:  Christian Wischke; Ying Zhang; Sachin Mittal; Steven P Schwendeman
Journal:  Pharm Res       Date:  2010-07-29       Impact factor: 4.200

2.  Long-term Fenretinide treatment prevents high-fat diet-induced obesity, insulin resistance, and hepatic steatosis.

Authors:  Frederic Preitner; Nimesh Mody; Timothy E Graham; Odile D Peroni; Barbara B Kahn
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-10-13       Impact factor: 4.310

3.  Metabolism of the chemopreventive retinoid N-(4-hydroxyphenyl)retinamide by mammary gland in organ culture.

Authors:  R G Mehta; T A Hultin; R C Moon
Journal:  Biochem J       Date:  1988-12-01       Impact factor: 3.857

4.  Fenretinide metabolism in humans and mice: utilizing pharmacological modulation of its metabolic pathway to increase systemic exposure.

Authors:  Jason P Cooper; Kyunghwa Hwang; Hardeep Singh; Dong Wang; C Patrick Reynolds; Robert W Curley; Simon C Williams; Barry J Maurer; Min H Kang
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

5.  Inhibitory effects of fenretinide metabolites N-[4-methoxyphenyl]retinamide (MPR) and 4-oxo-N-(4-hydroxyphenyl)retinamide (3-keto-HPR) on fenretinide molecular targets β-carotene oxygenase 1, stearoyl-CoA desaturase 1 and dihydroceramide Δ4-desaturase 1.

Authors:  Eugenia Poliakov; William Samuel; Todd Duncan; Danielle B Gutierrez; Nathan L Mata; T Michael Redmond
Journal:  PLoS One       Date:  2017-04-27       Impact factor: 3.240

6.  Retinoids, breast cancer and NK cells.

Authors:  M L Villa; E Ferrario; D Trabattoni; F Formelli; G De Palo; A Magni; U Veronesi; E Clerici
Journal:  Br J Cancer       Date:  1993-11       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.